Zhengye Biotechnology Holding Limited (ZYBT) Key Metrics
ZYBT key metrics, 2021–2025
Fiscal year ended December 31, 2025 · Chinese yuanZYBT returns How much profit the business earns on the capital it uses.
ZYBT financial health Debt, liquidity and how easily interest is covered.
ZYBT efficiency & capital use Working capital cycle and where the cash goes.
ZYBT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ZYBT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ZYBT cash returned to shareholders
ZYBT key metrics in Chinese yuan
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Returns & profitability | |||||
| Return on equity (ROE) | −26.1% | 4.1% | 11.1% | 16.6% | 14.6% |
| Return on invested capital (ROIC) | −19.9% | 4.4% | 11.0% | 17.9% | 15.8% |
| Return on assets (ROA) | −15.0% | 2.3% | 6.2% | 9.7% | 8.7% |
| Return on tangible assets | −18.3% | 2.4% | 6.5% | 9.3% | 9.0% |
| Free cash flow margin | 0.6% | 7.1% | 17.3% | −3.8% | 2.5% |
| Income quality (OCF / net income) | — | 3.63 | 1.53 | 0.37 | 0.82 |
| Financial health | |||||
| Total debt | CN¥75.1M | CN¥4.8M | CN¥89.8M | CN¥64.9M | CN¥30.0M |
| Cash & short-term investments | CN¥51.9M | CN¥18.6M | CN¥16.3M | CN¥9.7M | CN¥6.3M |
| Net debt | CN¥23.2M | −CN¥13.8M | CN¥73.6M | CN¥55.1M | CN¥23.7M |
| Debt / equity | 0.30 | 0.02 | 0.33 | 0.22 | 0.11 |
| Debt / assets | 0.17 | 0.01 | 0.18 | 0.12 | 0.07 |
| Net debt / EBITDA | — | −0.32 | 1.02 | 0.64 | 0.34 |
| Current ratio | 1.14 | 1.31 | 1.37 | 1.41 | 1.31 |
| Quick ratio | 0.82 | 0.88 | 0.98 | 1.04 | 0.97 |
| Interest coverage | -20.1 | 4.2 | 10.2 | 23.2 | 50.1 |
| Working capital | CN¥16.9M | CN¥41.7M | CN¥55.4M | CN¥62.1M | CN¥39.3M |
| Invested capital | CN¥273.0M | CN¥270.2M | CN¥346.4M | CN¥351.6M | CN¥291.2M |
| Tangible asset value | CN¥252.0M | CN¥329.8M | CN¥323.0M | CN¥337.4M | CN¥306.8M |
| Net current asset value | CN¥7.7M | CN¥36.9M | CN¥45.0M | CN¥51.5M | CN¥38.5M |
| Capital allocation | |||||
| Dividends paid | CN¥16.0M | CN¥16.0M | CN¥39.5M | CN¥21.4M | CN¥11.0M |
| Dividend payout ratio | — | 141.7% | 125.4% | 45.8% | 28.4% |
| Dividends + buybacks / free cash flow | — | 120.7% | 107.8% | — | 204.3% |
| Capex / revenue | 10.9% | 14.9% | 5.5% | 10.5% | 12.3% |
| Capex / operating cash flow | 94.7% | 67.7% | 24.1% | 157.6% | 83.0% |
| Capex / depreciation | 0.49 | 1.15 | 0.49 | 1.45 | 1.65 |
| R&D / revenue | 15.5% | 6.9% | 5.6% | 5.2% | 5.3% |
| SG&A / revenue | 64.4% | 34.3% | 31.5% | 24.4% | 27.2% |
| Efficiency | |||||
| Days sales outstanding | 122.4 | 155.7 | 201.5 | 165.8 | 174.2 |
| Days of inventory on hand | 192.2 | 223.7 | 253.7 | 169.3 | 179.6 |
| Days payables outstanding | 171.6 | 170.1 | 278.8 | 268.1 | 319.3 |
| Cash conversion cycle (days) | 143.0 | 209.3 | 176.5 | 67.0 | 34.5 |
| Receivables turnover | 2.98 | 2.34 | 1.81 | 2.20 | 2.09 |
| Payables turnover | 2.13 | 2.15 | 1.31 | 1.36 | 1.14 |
| Inventory turnover | 1.90 | 1.63 | 1.44 | 2.16 | 2.03 |
| Asset turnover | 0.25 | 0.38 | 0.42 | 0.54 | 0.48 |
| Average receivables | CN¥39.0M | CN¥79.5M | CN¥116.8M | CN¥118.2M | CN¥102.2M |
| Average payables | CN¥43.5M | CN¥44.3M | CN¥62.5M | CN¥78.4M | CN¥77.6M |
| Average inventory | CN¥48.7M | CN¥58.3M | CN¥56.9M | CN¥49.5M | CN¥43.6M |
| Intangibles / total assets | 12.5% | 4.6% | 3.3% | 3.7% | 2.7% |
Computed from ZYBT's annual financial statements (latest annual report filed April 28, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in Chinese yuan; data from EODHD. Averages use the opening and closing balance of each year.
ZYBT valuation and financial ratios
Zhengye Biotechnology earned a return on equity of −26.1% and a return on invested capital of −19.9% in fiscal 2025. It ended the year with CN¥75.1 million of debt and CN¥51.9 million in cash and short-term investments, net debt of CN¥23.2 million. It returned CN¥16.0 million to shareholders: CN¥16.0 million in dividends and CN¥0 in share buybacks.
See the ZYBT income statement, the ZYBT chart for price history, or the ZYBT stock overview for the latest quote and news.
ZYBT key metrics FAQ
What is Zhengye Biotechnology's return on equity?
Zhengye Biotechnology's return on equity (ROE) was −26.1% in fiscal 2025: net income of -CN¥69.8 million on average shareholders' equity of CN¥266.9 million.
What is Zhengye Biotechnology's ROIC?
Zhengye Biotechnology's return on invested capital was −19.9% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Zhengye Biotechnology have?
Zhengye Biotechnology had total debt of CN¥75.1 million at the end of fiscal 2025, a debt-to-equity ratio of 0.30.
What is Zhengye Biotechnology's current ratio?
Zhengye Biotechnology's current ratio was 1.14 at the end of fiscal 2025: current assets were 1.14 times current liabilities.